This article provides an abbreviated overview of the newly Federal Drug Administration (FDA)approved novel drugs of 2021-2022 with their respective approved indication(s). The FDA serves as the governing body that regularly evaluates and approves medications that will eventually be introduced to the market for routine use. These medications include both drugs that are the same or related to previously approved products (e.g., Extended indications of priorly approved medications) and novel drugs. By definition, a novel drug is an innovative product which serves to improve quality care in patient populations with unmet or advanced medical needs to overall advance patient care and public health. This article was employed to highlight medications that may be seen in practice and to heighten overall awareness of these new drugs. From January 1, 2021, through June 13, 2022, the FDA approved 66 drugs characterized as novel (Table 1). The four drugs highlighted in this article were selected based on potential inpatient and outpatient utility, disease-state prevalence, and overall innovative medication-based treatment approaches. The four highlighted drugs are included in Table 2.
Do M, Shin B, Lioudis E, Munn E. Novel Drugs Approved in 2021-2022. Transformative Medicine (T-Med). 2022; 1(3):72-77. doi: https://doi.org/10.54299/tmed/zcno1399.
Bacterial Infections and Mycoses Commons, Cardiovascular Diseases Commons, Medical Pharmacology Commons, Medicinal and Pharmaceutical Chemistry Commons, Other Pharmacy and Pharmaceutical Sciences Commons, Virus Diseases Commons